Floatz logo

Rivoceranib

Efficacy and Safety

Rongjie TaoSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Efficacy and Safety cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 4BB
Huazhi Rougan Granule
Shandong New Time Pharmaceutical Co., LTD
Phase 4BB
Inno-206
Women's Hospital School Of Medicine Zhejiang University
Phase 4BB
Eloxatin
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
TEGAFUR
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC

View all 14 →

Same molecule, other indications

Rivoceranib is also rated in:

gastric cancerDormant
BBB
Indicative ·
73 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
72 / 100
View asset →
ApatinibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →